Trial intelligence / Profile preview

Effect of Zamicastat on Bosentan PK in Healthy Subjects

NCT04991207Phase 1Completed

Sponsor
BIAL
Start
Feb 2018
Primary completion
May 2018
Modality
Small Molecules
Countries
1
01

Overview

Phase 1, open-label, single-arm trial of zamicastat in pulmonary arterial hypertension (PAH), sponsored by BIAL. Primary endpoints: Maximum observed concentration, Time to maximum concentration and 4 more. Started Feb 2018; status: completed.

02

Drugs

zamicastat
03

Conditions

pulmonary arterial hypertension (PAH)

Beyond the preview

Go deeper on NCT04991207.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT04991207.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call